Surrey Heartlands

Joint Formulary & PAD

Empagliflozin - Chronic Kidney Disease

You are here : Home > Formulary Search > Empagliflozin - Chronic Kidney Disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Empagliflozin
Indication :
Chronic Kidney Disease
Group Name :
Keywords :
CKD
Brand Names Include :
Jardiance
Important Information :
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to Empagliflozin initiation.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Chronic Kidney Disease
Supporting Documents :
4

Other Indications

Below are listed other indications that Empagliflozin is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Chronic Kidney Disease.

Committee Recommendations (2)

10 Feb 25 - Surrey Heartlands Medicines Safety Committee (MSC)

The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.

06 Mar 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves empagliflozin as a treatment option for treating chronic kidney disease in line with NICE TA942.

 NB: Check NICE guidance for recommended patient cohorts regarding eGFR.

Empagliflozin will be considered GREEN on the traffic light system.

Key considerations:

  • If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist diabetes team may be prudent prior to empagliflozin initiation.